Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2008 3
2009 2
2010 5
2011 4
2012 2
2013 2
2014 4
2015 9
2016 6
2017 9
2018 4
2019 4
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

46 results
Results by year
Filters applied: . Clear all
Page 1
Therapies for acute myeloid leukemia: vosaroxin.
Sayar H, Bashardoust P. Sayar H, et al. Onco Targets Ther. 2017 Aug 7;10:3957-3963. doi: 10.2147/OTT.S121477. eCollection 2017. Onco Targets Ther. 2017. PMID: 28860803 Free PMC article. Review.
Vosaroxin, a quinolone-derivative chemotherapeutic agent, was considered a promising drug for the treatment of acute myeloid leukemia (AML). ...The study demonstrated better complete remission rates with vosaroxin, but there was no statistically significant overall
Vosaroxin, a quinolone-derivative chemotherapeutic agent, was considered a promising drug for the treatment of acute myeloid leukemia
The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia.
Paubelle E, Zylbersztejn F, Thomas X. Paubelle E, et al. Expert Opin Drug Discov. 2017 Jul;12(7):747-753. doi: 10.1080/17460441.2017.1331215. Epub 2017 May 22. Expert Opin Drug Discov. 2017. PMID: 28504025 Review.
Areas covered: Herein, the authors provide a comprehensive review of the preclinical development of vosaroxin. This includes coverage of vosaroxin's mechanism of action in addition to its pharmacology and of the main studies reported over the past few years with …
Areas covered: Herein, the authors provide a comprehensive review of the preclinical development of vosaroxin. This includes coverage …
Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape.
Sedov V, Stuart RK. Sedov V, et al. Ther Adv Hematol. 2017 Jun;8(6):185-195. doi: 10.1177/2040620717703012. Epub 2017 Apr 21. Ther Adv Hematol. 2017. PMID: 28567238 Free PMC article. Review.
There is no standard of care for relapsed/refractory (R/R) AML, and no new therapies have shown consistently superior outcomes in this setting in over two decades. Vosaroxin is an anticancer quinolone derivative (AQD) that was evaluated in combination with cytarabine for t …
There is no standard of care for relapsed/refractory (R/R) AML, and no new therapies have shown consistently superior outcomes in this setti …
Vosaroxin induces mitochondrial dysfunction and apoptosis in cervical cancer HeLa cells: Involvement of AMPK/Sirt3/HIF-1 pathway.
Zhao XL, Yu CZ. Zhao XL, et al. Chem Biol Interact. 2018 Jun 25;290:57-63. doi: 10.1016/j.cbi.2018.05.011. Epub 2018 May 22. Chem Biol Interact. 2018. PMID: 29800573
Vosaroxin is a quinolone-derivative anticancer agent with inhibitory activity on type II DNA topoisomerases (TOP2). ...Vosaroxin also induced apoptosis and increased caspase-3 activity in HeLa cells. ...
Vosaroxin is a quinolone-derivative anticancer agent with inhibitory activity on type II DNA topoisomerases (TOP2). ...Vosaroxin
Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia.
Hotinski AK, Lewis ID, Ross DM. Hotinski AK, et al. Expert Opin Pharmacother. 2015 Jun;16(9):1395-402. doi: 10.1517/14656566.2015.1044437. Epub 2015 May 10. Expert Opin Pharmacother. 2015. PMID: 25958926 Review.
INTRODUCTION: Vosaroxin is a first-in-class anti-cancer quinolone that inhibits topoisomerase-II leading to cell cycle arrest and apoptosis. ...AREAS COVERED: We review the data from the published clinical trials of vosaroxin, including the recently presented Phase …
INTRODUCTION: Vosaroxin is a first-in-class anti-cancer quinolone that inhibits topoisomerase-II leading to cell cycle arrest and apo …
Vosaroxin : a novel antineoplastic quinolone.
Abbas JA, Stuart RK. Abbas JA, et al. Expert Opin Investig Drugs. 2012 Aug;21(8):1223-33. doi: 10.1517/13543784.2012.699038. Epub 2012 Jun 23. Expert Opin Investig Drugs. 2012. PMID: 22724917 Review.
INTRODUCTION: The antineoplastic quinolone derivative vosaroxin (SNS-595, Sunesis, South San Francisco, CA, USA) was first described in 2002. ...EXPERT OPINION: Despite its structural dissimilarity, vosaroxin has mechanisms of action similar to the anthracyclines an …
INTRODUCTION: The antineoplastic quinolone derivative vosaroxin (SNS-595, Sunesis, South San Francisco, CA, USA) was first described …
Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Nogueras González GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes J, Ward R, Craig A, Ravandi F. Daver N, et al. Haematologica. 2017 Oct;102(10):1709-1717. doi: 10.3324/haematol.2017.168732. Epub 2017 Jul 20. Haematologica. 2017. PMID: 28729302 Free PMC article.
Vosaroxin is an anti-cancer quinolone-derived DNA topoisomerase II inhibitor. ...The initial 22 patients received vosaroxin 90 mg/m(2) on days 1 and 4 with decitabine 20 mg/m(2) on days 1-5 every 4-6 weeks for up to seven cycles. ...
Vosaroxin is an anti-cancer quinolone-derived DNA topoisomerase II inhibitor. ...The initial 22 patients received vosaroxin 90
Targeting acute myeloid leukemia with TP53-independent vosaroxin.
Benton CB, Ravandi F. Benton CB, et al. Future Oncol. 2017 Jan;13(2):125-133. doi: 10.2217/fon-2016-0300. Epub 2016 Sep 12. Future Oncol. 2017. PMID: 27615555 Free PMC article. Review.
Vosaroxin is a quinolone compound that intercalates DNA and induces TP53-independent apoptosis, demonstrating activity against acute myeloid leukemia (AML) in Phase I-III trials. Here, we examine vosaroxin's mechanism of action and pharmacology, and we review its us
Vosaroxin is a quinolone compound that intercalates DNA and induces TP53-independent apoptosis, demonstrating activity against acute
Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
Liu F, Knight T, Su Y, Edwards H, Wang G, Wang Y, Taub JW, Lin H, Sun L, Ge Y. Liu F, et al. Target Oncol. 2019 Jun;14(3):351-364. doi: 10.1007/s11523-019-00638-4. Target Oncol. 2019. PMID: 31115744
Finally, colony-forming assays were conducted on normal human CD34+ cord blood cells and primary acute myeloid leukemia patient samples to determine the effect of venetoclax and vosaroxin on normal hematopoietic and leukemic progenitor cells. RESULTS: We found that venetoc …
Finally, colony-forming assays were conducted on normal human CD34+ cord blood cells and primary acute myeloid leukemia patient samples to d …
The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review.
Short NJ, Ravandi F. Short NJ, et al. Expert Rev Hematol. 2016 Jun;9(6):529-34. doi: 10.1080/17474086.2016.1187063. Epub 2016 May 24. Expert Rev Hematol. 2016. PMID: 27158854 Review.
Given the encouraging results of vosaroxin in the relapsed/refractory setting, several studies are also evaluating vosaroxin in older patients with untreated AML who are not candidates for intensive chemotherapy. ...As vosaroxin has been associated with incre …
Given the encouraging results of vosaroxin in the relapsed/refractory setting, several studies are also evaluating vosaroxin i …
46 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page